Clinical Trials Directory

Trials / Completed

CompletedNCT00325299

Magnesium After Alcohol Withdrawal Treatment

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
178 (planned)
Sponsor
Finnish Foundation for Alcohol Studies · Academic / Other
Sex
All
Age
20 Years – 64 Years
Healthy volunteers
Not accepted

Summary

The primary purpose is to see if magnesium tablet supplementation will decrease elevated GGT enzyme activity in alcoholic patients immediately after they had been treated for alcohol withdrawal. The secondary aims are to find out whether supplementation decreases the activity of ASAT and ALAT enzymes, increases muscle strength, decreases blood pressure and decreases depressive symptoms among these patients.

Detailed description

Magnesium (Mg) deficiency is common among alcoholics. Animal studies have shown that magnesium deficiency aggravates the hepatic damage caused by alcohol. One study on chronic alcoholics suggested that magnesium supplementation over six weeks decreases abnormally high activities of three enzymes related to liver function: serum gamma-glutamyltransferase (GGT), aspartate-aminotransferase (ASAT) and alanine-aminotransferase (ALAT), and increases muscle strength \[4\]. These results were, however, significant at the 5% level only when a 1-sided test was applied. It seems that magnesium supplementation may improve liver recovery after a drinking bout, but the evidence is not yet strong enough to warrant clear recommendations for clinical practice. Magnesium deficiency may also be one of the symptoms of depression and may aggravate hypertension. The primary purpose of the present randomized, parallel group, double blind trial is to see if oral magnesium supplementation will decrease elevated GGT enzyme activity in alcoholic patients immediately after they had been treated for alcohol withdrawal. The secondary aims are to find out whether supplementation decreases the activity of ASAT and ALAT enzymes, increases muscle strength, decreases blood pressure and decreases depressive symptoms among these patients.

Conditions

Interventions

TypeNameDescription
DRUGMagnesium

Timeline

Completion
2005-09-01
First posted
2006-05-12
Last updated
2006-05-12

Locations

1 site across 1 country: Finland

Source: ClinicalTrials.gov record NCT00325299. Inclusion in this directory is not an endorsement.